Therapeutic Effect of Risperidone on the Refractory Schizophrenia: a Single-Blinded Comparison with Haloperidol / 신경정신의학
Journal of Korean Neuropsychiatric Association
;
: 1111-1120, 1998.
Article
Dans Coréen
| WPRIM
| ID: wpr-107819
ABSTRACT
OBJECTIVES:
We attempted to investigate clinical efficacy of risperidone a new antipsychotic agent with high safety and without life-threatening side effect such as agranulocytosis, in refractory schizophrenia compared with a haloperidol, well-known antipsychotic agent.METHODS:
Thirty-four subjects(risperidone group 16, haloperidol group 18), who had been proved to be refractory schizophrenics with prospective antipsychotic treatment with at least 2 antipsychotic agents belonging to different chemical groups from each other, were examined with Clinical Global Impression(CGI) and 18-item Brief Psychiatric Rating Scale(BPRS) at 0, 2nd, 4th, 8th, and 12th week from start of drug administration. Those scales were rated in the single-blind manner.RESULTS:
End-point response rate of risperidone was 25%(4 subjects), and that of haloperidol was zero. Difference of the response rates between risperidone and haloperidol was statistically significant. Broader spectrum of symptoms was improved with risperidone treatment than with haloperidol.CONCLUSION:
Risperidone is an antipsychotic agent that clinicians can primarily and effectively try in the refractory schizophrenics with high safety.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Schizophrénie
/
Neuroleptiques
/
Poids et mesures
/
Études prospectives
/
Rispéridone
/
Agranulocytose
/
Halopéridol
Type d'étude:
Essai clinique contrôlé
/
Étude observationnelle
langue:
Coréen
Texte intégral:
Journal of Korean Neuropsychiatric Association
Année:
1998
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS